Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2022

In 2022, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 4.59% of shares outstanding on 14 Jan 2022 to 7.62% on 30 Dec 2022, a change of +3.03 percentage points. The year's high was 8.71% on 15 Jun 2022 and its low 4.59% on 14 Jan 2022, averaging 6.43% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.03 days on 30 Nov 2022. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
4.59% (14 Jan 2022)
End of year
7.62% (30 Dec 2022)
Change
+3.03 pp
High
8.71% (15 Jun 2022)
Low
4.59% (14 Jan 2022)
Average
6.43%
Highest days to cover
9.03 (30 Nov 2022)
SEC filings marked
8

Every report in 2022

EAGLE PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20224.59%6.15
31 Jan 20225.15%5.45
15 Feb 20225.21%5.59
28 Feb 20224.68%5.45
15 Mar 20225.34%5.83results (8-K), 10-K filed
31 Mar 20225.57%4.20
14 Apr 20225.40%5.48
29 Apr 20226.60%8.19
13 May 20227.14%6.6410-Q filed, results (8-K)
31 May 20227.45%6.55
15 Jun 20228.71%8.60
30 Jun 20228.14%6.11
15 Jul 20227.89%8.95
29 Jul 20227.93%7.75
15 Aug 20226.18%5.0910-Q filed, results (8-K)
31 Aug 20226.37%5.45
15 Sep 20225.28%3.98
30 Sep 20226.80%3.91
14 Oct 20227.37%5.63
31 Oct 20226.89%6.67
15 Nov 20227.04%4.50results (8-K), 10-Q filed
30 Nov 20226.38%9.03
15 Dec 20224.65%3.77
30 Dec 20227.62%5.57

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.